Clinic
Pafford Health Systems INC
Pafford Health Systems INC was paid $119K by Medicaid between Jul 2021 and Oct 2024, across 8 billing codes. Its largest line is U0002, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc — 44% of everything it billed.
33Billing provider infoPAFFORD HEALTH SYSTEMS INC
HOPE, AR 71801
HOPE, AR 71801
33aNPI1164027231assigned 12/04/2020
33bProvider typeClinic/Center
28Total paid$119K
24GClaims4,544
24DCodes billed8
24AFirst – last monthJul 2021 – Oct 2024
Compared with peers
Next to other Clinic/Center providers in Arkansas
Rank by total paid#32 of 77
Median peer was paid$68K
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 1,340 | $37K | |
| 2022 | 2,535 | $68K | |
| 2023 | 504 | $10K | |
| 2024incomplete | 165 | $3K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 44% | 1,804 | 1,261 | $52K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 42% | 740 | 571 | $50K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.5% | 413 | 333 | $8K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.2% | 291 | 240 | $4K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.1% | 147 | 131 | $2K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.7% | 295 | 214 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 14 | 14 | $102.96 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 840 | 692 | $62.63 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRESHAM, BENJAMIN (PRESIDENT)